Journal article
Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective.
- Zandi S a Clinic for Vitreoretinal Diseases , Swiss Eye Institute and Berner Augenklinik am Lindenhofspital , Bern , Switzerland.
- Bodaghi B b DHU ViewRestore, UPMC , Sorbonne Universities, APHP , Paris , France.
- Garweg JG a Clinic for Vitreoretinal Diseases , Swiss Eye Institute and Berner Augenklinik am Lindenhofspital , Bern , Switzerland.
- 2018-08-11
Published in:
- Ocular immunology and inflammation. - 2018
Acyclovir
antivirals
treatment
valacyclovir
viral anterior uveitis
Acyclovir
Antiviral Agents
Bromodeoxyuridine
Chikungunya Fever
Cytomegalovirus Infections
Eye Infections, Viral
Famciclovir
Herpes Simplex
Herpes Zoster Ophthalmicus
Humans
Rubella
Uveitis, Anterior
Valacyclovir
Zika Virus Infection
English
PURPOSE
To define a clinically tailored therapeutic strategy for the treatment of viral anterior uveitis (VAU).
METHODS
A PubMed search spanning the past 5 years was conducted using the MesH-terms "viral anterior uveitis" and "therapy."
RESULTS
The herpes simplex virus (HSV), the varicella zoster virus (VZV), and the cytomegalovirus (CMV) are the predominant pathogens in VAU. Other viruses, including rubella, chikungunya, and zika, have been linked with distinct forms of the disease. Depending on the causative agent and the host immunocompetence, the mainstay treatment for suspected VAU is a combination of topical or systemic antivirals and topical corticosteroids, supplemented with cycloplegics and intraocular-pressure-lowering medication.
CONCLUSIONS
Oral acyclovir, valacyclovir, and famciclovir are the mainstay of treatment for HSV- and VZV-induced infections. Brivudin serves as an alternative in insufficiently responsive cases. CMV-induced infections respond well to valganciclovir. A 3- to 12-month course of prophylactic treatment against recurrences is worth considering.
To define a clinically tailored therapeutic strategy for the treatment of viral anterior uveitis (VAU).
METHODS
A PubMed search spanning the past 5 years was conducted using the MesH-terms "viral anterior uveitis" and "therapy."
RESULTS
The herpes simplex virus (HSV), the varicella zoster virus (VZV), and the cytomegalovirus (CMV) are the predominant pathogens in VAU. Other viruses, including rubella, chikungunya, and zika, have been linked with distinct forms of the disease. Depending on the causative agent and the host immunocompetence, the mainstay treatment for suspected VAU is a combination of topical or systemic antivirals and topical corticosteroids, supplemented with cycloplegics and intraocular-pressure-lowering medication.
CONCLUSIONS
Oral acyclovir, valacyclovir, and famciclovir are the mainstay of treatment for HSV- and VZV-induced infections. Brivudin serves as an alternative in insufficiently responsive cases. CMV-induced infections respond well to valganciclovir. A 3- to 12-month course of prophylactic treatment against recurrences is worth considering.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1080/09273948.2018.1498109
- PMID 30096015
- Persistent URL
- https://sonar.ch/global/documents/192965
Statistics
Document views: 19
File downloads: